Please sign in to follow a disease.
Can an experimental antibody boost chemo's power against lymphoma?
NCT ID NCT07081022
First seen Sep 04, 2026 · Last updated Sep 04, 2026
Summary
This Phase 2 trial tests whether adding an experimental antibody called JS203 to standard chemotherapy regimens can shrink tumors in people with B-cell non-Hodgkin's lymphoma, a cancer of immune cells. The study enrolls adults aged 18 to 80 whose cancer cells carry the CD20 marker and who have at least one measurable tumor. Participants receive JS203 alongside one of several chemo combinations, and researchers measure how many people respond and how long the response lasts.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JS203, an experimental antibody, combined with standard chemotherapy regimens
- What this could lead to
- If it works, this could offer a more effective treatment option for B-cell non-Hodgkin's lymphoma, potentially improving response rates and remission duration.
- What could go wrong
- This is an early Phase 2 trial, so the combination may not prove more effective than existing treatments. Side effects from adding JS203 to chemotherapy are possible and could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be enrolled： * Age range: 18 to 80 years old (inclusive), both male and female are acceptable； * ECOG: 0-2； * B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed； * At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening； Exclusion Criteria: * A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)； * Previously received CD20-CD3 bispecific antibody treatment； * Previous allogeneic hematopoietic stem cell transplantation； * Previous solid organ transplantation； * History of autoimmune diseases； * Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)； * Patients with a history of progressive multifocal leukoencephalopathy (PML)； * A known or suspected history of CNS lymphoma (including primary or secondary)； * There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-cell non-Hodgkin's lymphoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.